CAS: 274-95-3; Imidazo[1,2-A]Pyrimidine

相似化合物

6840-21-7 865156-68-9 944906-56-3

1,3,5-三嗪-2,4,6-三胺,N,N'''-1,2-乙二基二[n-[3-[[4,6-二[丁基(2,2,6,6-四甲基-4-哌啶基)氨基]-1,3,5-三嗪-2-基]氨基]丙基]-N,N''-二丁基-N,N''-二(2,2,6,6-四甲基-4-哌啶基)-,氯乙醛 以 乙醇 用作溶剂,以100%的收率获得咪唑并[1,2-A]嘧啶
参考文献:从合成的简化海洋代谢物类似物到新的极光b激酶选择性变构抑制剂
标题:从合成的简化海洋代谢物类似物到新的极光b激酶选择性变构抑制剂
摘要:通过合成属于海绵的海洋吡咯-2-氨基咪唑代谢产物的苯并ceptors和oroidin的简化片段,可以实现对aurora B的显着抑制.激酶抑制作用的评估使得能够发现可合成获得的刚性炔属结构类似物el-228(1),其结构可以优化为有效的cj2-150(37).在这里,我们介绍了新的aurora B激酶抑制剂的合成,该抑制剂是通过有丝分裂调节进行癌症治疗的重要靶标.生物定向合成产生了几种纳摩尔抑制剂.优化的化合物cj2-150(37)在aurora B激酶的混合型抑制中显示了非atp竞争性变构作用模式.分子对接在变构位点" F"中确定了可能的结合模式,并强调了与蛋白质的关键相互作用.我们描述了新型支架的抑制力和特异性的提高以及作用机理的表征.
Doi:10.1021/acs.Jmedchem.0C02064

专利信息

专利号:US-11325912-B2
优先权日:2019-05-09
标题 :Regio-selective synthesis of imidazo[1,2-a]pyrimidines
发明人：CLAGG KYLE BRADLEY PASCUAL; WHITE NICHOLAS ANDREW; ZHANG HAIMING; GOSSELIN FRANCIS; NACK WILLIAM; O'SHEA PAUL D
权利人:GENENTECH INC
摘要:A method of regio-selectively synthesizing an imidazo-pyrimidine compound of formulae (XXa) or (XXb)comprising a step of coupling a first compound of formula XX-P1a or XX-P1b with a second compound of formula XX-P2This annulation reaction between β-ethoxy acrylamides and phosphorylated aminoimidazoles to furnish imidazo[1,2-a]pyrimidin-amines relies on steering effects from endocyclic and exocyclic phosphorylated aminoimidazoles. The reaction furnishes either 2-amino or 4-amino constitutional isomers of imidazo[1,2-a]pyrimidines with good yields and ranges of 90:10-99:1 regio-selectivity. The reaction is useful in the synthesis of various tracer molecules used in the study of neurological conditions such as where R3 and R4 together with the imidazole ring atoms to which they are bonded form a phenyl ring and the products are substituted benzimidazopyrimidines. The reaction can be generalized to form imidazo[1,2-a]pyrimidines substituted at either of their 2- and 4-positions by alkoxy or thioalkyl groups.

专利号:WO-2024137329-A1
优先权日:2022-12-20
标 题:Methods for the synthesis of complement factor d inhibitors and intermediates thereof
发明人：HASHIMOTO AKIHIRO; TIPPARAJU SURESH KUMAR
权利人:ALEXION PHARMA INC
摘要:The present disclosure provides methods for the synthesis of complement factor D inhibitors and intermediates thereof.

专利号:WO-2024019698-A1
优先权日:2022-07-18
标题 :Photocatalytic synthesis of alpha, beta unsaturated carbonyl compounds and their intermediates
发明人：SUGURI TAKUYA; MARUYAMA YOUICHIROU; LIM CHERN-HOOI; QIAN GANG; LIU YUE; COPE ELANA
权利人:JSR CORP; NEW IRIDIUM INC
摘要:Described herein is a process of producing α,β unsaturated acids and amides and their intermediates via a photocatalytic reaction in the presence of a photocatalyst, oxygen, and optionally a solvent. The photocatalyst contains a tungstic acid or a salt of a tungstic acid. The process is simple, clean, and energy efficient, and provides good conversion, good selectivity, good turnover, and easy purification of end products.

专利号:US-2018312534-A1
优先权日:2015-10-16
标题:Fluorescent anticancer platinum drugs
发明人：SARKAR ARINDAM; MANDAL SWADHIN KUMAR; SENGUPTA ANIRUDDHA; BISWAS GOUTAM; DUTTA PRADIP; SHARMA RUPALI; RAJ JUSTIN PAUL; SURYAVANSHI HEMANT; KUMARI SMITA
权利人:INVICTUS ONCOLOGY PVT LTD
摘要:The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to fluorescent platinum based compounds. The disclosure further relates to synthesis of said fluorescent platinum based compounds, nanoparticles and compositions comprising said fluorescent platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by the fluorescence changes between aforesaid platinum based compounds and corresponding free ligands, nanoparticles and compositions.

专利号:US-2017233877-A9
优先权日:2011-06-17
标 题 :Synthesis of hetero compounds using dialkylcarbonate quaternation

专利号:US-10000487-B2
优先权日:2015-11-20
标 题 :Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
发明人：SPRENGELER PAUL A; REICH SEIGFRIED H; WEBBER STEPHEN E; ERNST JUSTIN T
权利人:EFFECTOR THERAPEUTICS INC
摘要:The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. n nFor Formula IA and Formula IB compounds A 1 , A 2 , A 3 , A 4 , W 1 , W 2 , Y, X, R 1 , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , R 6 , R 7 , R 8 , R 9 , R 9a , R 9b , R 10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.